WW:
<<This is not an attack on you, but I do think you should defend your attack on sugn with some valid reasoning.>>
First, I am not attacking SUGN. I am searching for information!
You should spent few moments and read my past posts here and other SI boards. Who knows, maybe will help you.
If you find single person who like more than me what is SUGN trying to do ( I mean science and drug pipeline as cancer therapy, not necessarily how management keeps company going), than ...
This board is not reserved for *good* post only. Criticism (when appropriate) and constructive dialogue can help anyone, not blind or misinform. If I am wrong, please correct me, but with argument not with philosophy. I will appreciate it, and I think other lurks as well.
<<What is your point? SUGN's product has already been shown to be non-toxic ( the purpose of Phase I trials).>>
Are you saying that SU101 is non-toxic, or better said without side effects which may limit drug potential? If yes, please document or provide source for claim. Understand me, I am not saying that SU101 has non-tolerable severe side effects (like some other cytotoxic drug on market or in development), but it is not free of side effects.
<<Thalidomide has nothing to do with SUGN. >>
Not true, it is drug-competitor for SU101 (and SU5416); brain, prostate, lung, ...cancer. So, what was SUGN point to mentioned Thalidomide (in bad light) in press?
<<Unless you have just crawled out from under a rock, you should already know that Thalidomide is toxic.>>
Rock is in your head. I know more about Thalidomide than you can even image.
<<More funding means (to me) a greater chance of success and an increase in confidence of the company.>>
Did you ask yourself (as one who claim to have training in finance) are there other instrument to provide necessary cash for ongoing (promising, yes very promising) operations at SUGN? Like merge (with someone who can provide what SUGN needs, move bit and search what SUGN may need), or program partnering, or...
Today, when long and short term interest rate are headed to ~4, they are borrowing at 300% premium. If interest rate rise to ~8, than I will said that this is good financial deal, otherwise I see it as *average*. But, SUGN should be at much stronger position, and *force* investors (yes right, specially this days) for better deal.
<Why don't you just ask "Why is SUGN concentrating on colon cancer instead of all cancer">>
I said only METASTATIC colon cancer, why not ALL colon cancer? Think!
This is not attack on you, only defending my *search*.
Miljenko
|
